miR-21: a promising biomarker for the early detection of colon cancer

Purpose: The aim of this study was to compare the expression of miR-21 gene in stages II-IV of formalin-fixed paraffin-embedded (FFPE) tissue in patients with colon cancer and introduce miR-21 as a potential molecular marker for detection of colon cancer in the early stages.

Introduction: Currently, identification of key molecules involved in the pathogenesis of cancer is one of the areas under consideration. miRNAs, are small RNAs which have been identified in many cancers. In this study, we investigated the expression of miR-21 in three pathologic stages in patients with colon cancer in the north of Iran.

Patients and methods: A total of 40 FFPE samples were obtained from patients with stages II, III, and IV from hospitals in Mazandaran and Golestan provinces. After extraction of RNA, treatment with DNase I and cDNA synthesis was performed and miR-21 expression was assessed by qPCR. Then, the data were analyzed using statistical software R (3.4.3).

Results: The expression of miR-21 in stage II was significantly different from stage IV. However, no significant difference was observed between the other stages. In stage II, the level of miR-21 expression was higher in men than women. Moreover, in the second pathological stage, miR-21 expression was reduced in patients with adjacent lymphoid tissue engagement. In addition, the expression of miR-21 in grade I was significantly higher than grade II.

Conclusion: The results of this study suggest that miR-21 can be a diagnostic marker for early stages of colon cancer, especially in men. It can also be considered as a good candidate for targeted treatment of colon cancer in the early stages of the disease. Furthermore, for the first time, we suggested that miR-21 can be a good molecular marker for classification of the stages of colon cancer.

Keywords: colon cancer, pathological stages, miR-21, gene expression, biomarker, early diagnosis

Introduction

The exact diagnosis and effective treatment of cancer depends on the exact recognition of its molecular characteristics at different stages of the cancer, if this disease is diagnosed early, it can be treated efficiently. Colon cancer is pathologically classified into five stages (0, I, II, III, IV). However, the same treatment for patients at each stage does not result in the same consequence. This may be due to the presence of different molecular features in tumor cells in different stages. Therefore, better understanding of the molecular characteristics of cancer cells helps to form a better classification of tumors. Functional differences in the types of tumors and various stages of cancers are related to the expression of the miRNAs. Moreover, the expressions of the miRNAs are related to the clinical and biological features of the tumor, such as tissue type, differentiation, invasion and response to treatment. Furthermore, since miRNAs are

Correspondence: Sohrab Boozarpour
Basirat BLV, Gonbad Kavous University, Shahid Fallahy St, Gonbad Kavous, Golestan Province 4971799151, Iran
Tel +98 173 326 8883
Fax +98 173 326 8882
Email so.boozarpour@gonbad.ac.ir

OncoTargets and Therapy 2019:12 5601–5607
Submit your manuscript | www.dovepress.com
DovePress

© 2019 Dehghan et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
the key regulators of gene expression and have unique features among the molecular markers, the use of miRNAs to classify tumor progression stages is more appropriate than other molecular markers such as mRNA and proteins.\textsuperscript{4} miRNAs are subgroups of non-coding RNAs, with a length of 17–22 nucleotides that are evolutionally protected and their roles in the onset and progression of various cancers has recently been confirmed.\textsuperscript{3,4} These molecules, through their seed regions (2–7 nucleotide) attach to the microRNA response element (MRE) regions at the 3’-UTR of mRNA of targeted genes and regulate their expression by inhibiting translation or degradation and depending on the type of genes that they inhibit, they play the role of tumor suppressors or oncogenes.\textsuperscript{5,6} Due to the coupling of miRNAs with a large number of target mRNAs, miRNAs can target the expression of many genes in multiple paths.\textsuperscript{7} Bioinformatics analyses showed that more than 50% of the human genome is regulated by the miRNAs which include more than 1% of the human genome.\textsuperscript{8,9} Altering miR-21 expression as a crucial miRNA has been shown in many cancers.\textsuperscript{10} miR-21 with targeting genes such as PDCD4,\textsuperscript{10} NF-KB,\textsuperscript{11} RECK,\textsuperscript{12} PTEN,\textsuperscript{13} TPM1\textsuperscript{14} and by regulating apoptosis,\textsuperscript{15} cell proliferation and migration\textsuperscript{16} plays an important role in the types of cancers, including gastrointestinal cancers.\textsuperscript{17,18} Our goal in this study was to evaluate and compare the expression of miR-21 in colon cancer stages II–IV stages, in order to evaluate miR-21 as a potential biomarker, for prognosis, and examining its expression in various stages of colon cancer.

### Materials and methods

#### Population studied (experimental design)

A total of 40 formalin-fixed paraffin-embedded (FFPE) samples from the stages of II, III and IV of colon cancer which pathologically approved were collected from Imam and Shafa hospitals in Sari city and Khatam al-Anbia hospital in Gonbad kavous city between 1996 and 2000 and their pathological information was recorded Table 1.

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Khatam al-Anbia hospital.

#### Extracting miRNA

First, sections with a diameter of 15 microns from FFPE samples were prepared by using a microtome system, and deparaffinization performed based on ethanol and xylene combination protocols. In order to extract the miRNA from the paraffin tissue, the miRNeasy FFPE kit (Qiagen NV, Hilden, Germany) was used, according to the manufacturer’s protocol, which extracted RNAs with a length of less than 200 nucleotides, including miRNAs. Then with the Pico Drop (Pico200, Quantica) device, the

| Variable                          | Levels | Stage II (n=17) | Stage III (n=13) | Stage IV (n=10) |
|----------------------------------|--------|----------------|-----------------|-----------------|
| Degree                           | Gl     | 13 (76%)       | 8 (61%)         | 0               |
|                                  | GII    | 4 (24%)        | 4 (31%)         | 7 (70%)         |
|                                  | GIII   | 0              | 1 (8%)          | 0               |
|                                  | GIV    | 0              | 0               | 3 (30%)         |
| Age (years)                      | ≤55    | 10 (59%)       | 9 (69%)         | 5 (50%)         |
|                                  | >55    | 7 (41%)        | 4 (31%)         | 5 (50%)         |
| Sex                              | Man    | 12 (71%)       | 8 (62%)         | 4 (40%)         |
|                                  | Female | 5 (29%)        | 5 (38%)         | 6 (60%)         |
| The size of the tumor            | ≤4     | 11 (65%)       | 11 (85%)        | 9 (90%)         |
|                                  | >4     | 6 (35%)        | 2 (15%)         | 1 (10%)         |
| The condition of lymph is involved| P*     | 2 (12%)        | 12 (92%)        | 9 (90%)         |
|                                  | N**    | 15 (88%)       | 1 (8%)          | 1 (10%)         |
| Location of the tumor            | Left colon | 11 (65%)     | 7 (54%)         | -               |
|                                  | Right colon | 6 (35%)      | 6 (46%)         | -               |
| Stage IV metastasis              | L***   | 8 (80%)        | -               | -               |
|                                  | AW**** | 2 (20%)        | -               | -               |

Notes: *Lymph involved; **no lymph involved; ***metastasis to the lymph nodes; ****metastasis to the abdominal wall.
extracted RNA concentration is assessed about 320 ng/µL and optical absorption ratio at wavelengths of 260 and 280 (A260/280) was 1.8–2 which indicates the proper quality of extracted RNAs.

**Synthesis of cDNA and quantitative real-time PCR**

The study of miR-21 proliferation was performed using the PARSGENOME MiR-Amp kit. The RNU6B was used as a reference gene to compare miR-21 expression in different stages. Firstly, by the PolyA polymerase enzyme, at the 3’ end of all RNAs, polyA tail were added according to the protocol. In the second step, PolyA RNAs were used to synthesize cDNA using Reverse Transcriptase enzyme. In the third step, the study of gene expression with specific primers of miR-21 and RNU6B, was performed using SYBR Green in qPCR technique. Each sample was amplified as a duplicated reaction which used, 2 µl cDNA (9-fold diluted) in each reaction and amplified as the following program by Step One Plus Real-Time PCR System (Applied Biosystems, Thermo Fisher Scientific, Wlatham, MA, USA): Initial denaturation for 5 minutes, at 95°C and 40 cycles, 95°C, 5 seconds, 63°C, 20 seconds, 72 °C, 30 seconds.

**Statistical analysis**

Analysis of Real Time PCR data was performed using R (3.4.3) software and all p-values were two-sided (inequality between groups was observed). Our primary goal was to investigate the difference in expression of the miR-21 in various stages of colon cancer and its role as a molecular biomarker in identifying the pathological stages of colon cancer. The expression of miR-21 in the specimens was calculated using the 2^−ΔCT. Data were analyzed by K-test and Mann Whitney (u-test). Then, the association of miR-21 expression with pathologic characteristics of patients was investigated.

**Ethics approval and informed consent**

All participants were informed about the purpose of the study and all signed the written informed consent. The study was approved by the Ethics Committee of Khatam al-Anbia hospital and the study was conducted in accordance with the Declaration of Helsinki.

**Results**

The study of the distribution of miR-21 expression data in all three stages by Kruskal-Wallis test indicated a lack of normal distribution of data and the comparison of the mean of expression of miR-21 in the three stages was statistically significant (p-value=0.04). This means that the average expression of this gene is different at least in one of the stages, therefore, the u-test was used. The results of this test showed that the mean expression of miR-21 gene in the studied patients had a significant difference in stage II compared to stage IV (p-value<0.05), However, there was no significant difference between stages II and III and stages III and IV (p-value>0.05) (Figure 1).

Assessment of miR-21 in all stages showed that the expression was higher in men than women, with the ratio of 2.27 fold-change (p-value=0.006) (Figure 2). This is due to the apparent difference in expression of miR-21 in stage II (p-value=0.0003). The expression of this gene in stages III and IV does not show a significant difference between men and women (Figure 3). Investigating the expression of miR-21 in different degrees of disease showed that expression of this gene in grade I specimens was greater than grade II (p-value=0.00002) (Figure 4).

Investigating the lymphatic vessels involved in the tumor with the disease stages showed that in most patients in stage III and IV, lymphatic vessels were involved, but in a few patients with stage II, the lymph’s vessels were involved. In this regard, the evaluation of the association of miR-21 expression with the state of the lymph involved in stage II disease indicates that miR-21 expression in patients with no lymph nodes is higher than those with lymph nodes involved in the tumor (p-value=0.03) (Figure 5).

In almost all patients in stage II and III, the tumor tissue involved the colon sigmoid (left colon), and patients
in stage IV more often metastasis to the lymph nodes. However, the expression of miR-21 did not reveal any relationship with the tumor site at different stages. Also, in metastatic samples (stage IV), no relationship was found between the expression of miR-21 and the presence of secondary tumor. In addition, the expression of miR-21 did not show any association with tumor size.

Discussion

The best way to diagnose and provide therapy for colon cancer is to pay attention to pathogenesis and its molecular events. miRNAs as the key molecules regulating gene expression plays an important role in the tumorigenicity and progression of cancers. miR-21 as an oncomir is widely expressed in tumor tissue of colon cancer, which increases cell proliferation, invasiveness and cancer progression.

Several in vivo and in vitro studies have been performed to investigate the role of oncogenicity of miR-21. For example, a study in 2009 in the United States by using mouse models and anti-miR-21 injections or siRNAs CDC25A showed that miR-21 could inhibit CDC25 and inducing tumors in the colon. In another study Muppala et al showed that c-SRC inhibition with siRNA-SRC ultimately inhibited miR-21 and thus did not inhibit PTEN and PDCD4.
tumor suppressor proteins, thereby inhibiting tumor growth and progression in colon cancer.

However, few studies have been conducted on the pattern of expression of miRNAs in various stages of cancer. The present study is a part of the early studies to classify stages and grades of colon cancer based on the miR-21 gene expression. The pattern of miR-21 gene expression in different stages of colon cancer has shown different results. However, most studies have reported the expression of miR-21 in stage II more than the other stages, and no significant difference has been reported in other stages. For example, Conev et al.25 showed that, if the miR-21 gene expression is high in patients with colon cancer stage II, they are prone to recurrence.

Higher prevalence of colon cancer in men than women is reported in most parts of the world.26 The gender-dependency of miR-21 and miR-16 expression was disclosed in human colorectal cancer by Hasáková et al.27 Our findings showed a significant increase of miR-21 gene expression in stage II colon cancer in males than in females (Figure 3). In agreement with our report, two cohort studies used a hybridization analysis to demonstrate higher expression of miR-21 in men than women.28,29 This tendency might be due to the activity of male hormones, for example, steroid male hormones such as testosterone, can affect the synthesis of Pri-miR-21.30 In addition, this increase could be caused by some risk factors such as unhealthy diet, obesity, and tobacco consumption which men are more exposed to.31 The significant difference in the lower stages can result from difference in access to medical care and their knowledge about colorectal cancer.32,33 This may also be due to the different expression of miR-21 isomirs in different stages of colon cancer.34 However, this trend was not observed in all studies.35

The amount of lymph involved in various stages of colon cancer was another pathologic factor assessed. One of the factors that has a crucial role in cancer development is inflammation.36 Some inflammatory pathways cause up-regulation of miR-21 such as S100P/RAGE and COX-2.37,38 Moreover, miR-21 expression, significantly activates various types of immune cells.39,40 Sacchi et al.41 revealed that activated mast cells could destroy lymphatic vessels to prevent cancer metastasis. Furthermore, the amount of lymph involved could be a suitable predictor of lymph node metastasis of submucosal colorectal cancer.32 Based on the results obtained from patients in stage II, the current study showed higher miR-21 expression in non-lymph specimens (p-value=0.03) (Figure 5). Accordingly, a high level expression of miR-21 can be indicative of the early stages of colon cancer and a low possibility of metastasis. So, it seems that miR-21 is one of the markers that is useful for sub-classifying colon cancer stage II.

Although some studies suggest a direct relationship between the expression of miR-21 and tumor size,14,42 the present study is unanimous with other studies in Iran, and rejects this relationship.43,44 Also, our data is consistent with another study in Iran which showed that there is no association between miR-21 expression and location of tumor and type of metastasis in colon cancer.45 These studies may suggest that the expression of miR-21 in Iranian colon cancer patients is not related to the occurrence of tumor and the type of metastasis, which is not unanimous with some studies in the world.46 In summary, the results of current studies indicate that the characteristics of colon cancer in Iranian patients are different than other communities.

Conclusion
Our findings reinforce the probability that miR-21 can be a diagnostic molecular marker in the early stages of colon cancer, especially in men. In addition miR-21 can be considered as a good candidate for molecular classification of colon cancer stage II as well as an appropriate therapeutic goal.

Acknowledgments
The authors of the paper are grateful to the cooperation of Dr Massoud Fahimi, the head of the central laboratory of Khatam-al-Anbia Hospital and Dr Mehdi Vakili Nezhad, the pathologist, for their advice in the pathological study. We also thank Dr Shaaban Ghalandarayeshi for help with the statistical analysis.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Houlston RS, Tomlinson IP. Polymorphisms and colorectal tumor risk. Gastroenterology. 2001;121(2):282–301.
2. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322(6):352–358. doi:10.1056/NEJM199002083220602
3. Kim M, Kasinski AL, Slack FJ. MicroRNA therapeutics in preclinical cancer models. Lancet Oncol. 2011;12(4):319–321. doi:10.1016/S1470-2045(11)70067-5
4. Schaefler A, Jung M, Kristiansen G, et al. MicroRNAs and cancer: current state and future perspectives in urologic oncology. Urol Oncol. 2010;28(1):4–13. doi:10.1016/j.urolonc.2008.10.021

5. Kozonoma A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014;42(Database issue):D68–73. doi:10.1093/nar/gkt1181

6. Wouters MD, van Gent DC, Hoeijmakers JH, Plokhof J. MicroRNAs, the DNA damage response and cancer. Mutat Res. 2011;717(1-2):54–66. doi:10.1016/j.mrfmmm.2011.03.012

7. Friedman RC, Farhi KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92–105. doi:10.1101/gr.082701.108

8. Babashah S, Soleimani M. The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur J Cancer. 2011;47(8):1127–1137. doi:10.1016/j.ejca.2011.02.008

9. Kanellopoulou C, Monticelli S. A role for microRNAs in the development of the immune system and in the pathogenesis of cancer. Semin Cancer Biol. 2008;18(2):79–88. doi:10.1016/j.semcancer.2008.01.002

10. Lu Z, Liu M, Shi J, et al. MicroRNA-21 promotes APC-mediated Wnt signaling and colon cancer cell growth. Cancer Res. 2007;67(15):7263–7270. doi:10.1158/0008-5472.CAN-07-1385

11. Fujita S, No T, Mizumoto T, et al. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J Mol Biol. 2008;378(3):492–504. doi:10.1016/j.jmb.2008.03.015

12. Gabriely G, Wurdinger T, Kesari S, et al. MicroRNA 21 promotes tumourigenicity of glioma stem cells. J Neurooncol. 2008;87(3):215–225. doi:10.1007/s11060-008-9532-y

13. Saxena A, Tammail R, Ramana KV, Srivastava SK. Aldose reductase inhibition prevents colon cancer growth by restoring phosphatase and tensin homolog through modulation of miR-21 and FOXO3a. Antioxid Redox Signal. 2013;18(11):1249–1262. doi:10.1089/ars.2012.4643

14. Wang P, Zou F, Zhang X, et al. MicroRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res. 2009;69(20):8157–8165. doi:10.1158/0008-5472.CAN-09-1996

15. Hatley ME, Patrick DM, Garcia MR, et al. Modulation of K-Ras-independent lung tumorigenesis by microRNA-21. J Natl Cancer Inst. 2010;102(24):1840–1849. doi:10.1093/jnci/djv439

16. Xu J, Zhang W, Lv Q, Zhu D. Overexpression of miR-21 promotes the proliferation and migration of cervical cancer cells via the inhibition of PTEN. Oncol Rep. 2015;33(6):3108–3116. doi:10.3892/or.2015.3931

17. Schetter AJ, Nguyen GH, Bowman ED, et al. Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res. 2009;15(18):5878–5887. doi:10.1158/1078-0432.CCR-09-0627

18. Ribas N, Ni X, Haffen M, et al. miR-21: an angioded receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009;69(18):7165–7169. doi:10.1158/0008-5472.CAN-09-1448

19. Ju K, Wang N, Zou H, et al. miR-21 promotes cell cycle progression and chemoresistance of colon cancer cells. Cancer Res. 2010;70(10):4152–4161. doi:10.1158/0008-5472.CAN-09-3696

20. Yu N, Jiang Y, Wang Y, et al. miR-21 and miR-29 downregulate PTEN expression and promote colorectal cancer progression. Cancer Lett. 2010;293(1):120–128. doi:10.1016/j.canlet.2010.05.012

21. Saxena A, Tammail R, Ramana KV, Srivastava SK. Aldose reductase inhibition prevents colon cancer growth by restoring phosphatase and tensin homolog through modulation of miR-21 and FOXO3a. Antioxid Redox Signal. 2013;18(11):1249–1262. doi:10.1089/ars.2012.4643

22. Yu Y, Nangia-Makker P, Farhana L, Rajendra SG, Levi E, Majumdar AP, miR-21 and miR-145 cooperation in regulation of colon cancer stem cells. Mol Cancer. 2015;14:98. doi:10.1186/s12943-014-0279-9

23. Wang P, Zou F, Zhang X, et al. MicroRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res. 2009;69(20):8157–8165. doi:10.1158/0008-5472.CAN-09-1996

24. Muppala S, Mudduluru G, Leupold JH, Buergy D, Sleeman JP, Allgayer H. CD24 induces expression of the oncomir miR-21 via Src, and CD24 and Src are both post-transcriptionally downregulated by the tumor suppressor miR-34a. PLoS One. 2013;8(3):e59563. doi:10.1371/journal.pone.0059563

25. Conen NV, Donev IS, Konsoulou-Kirova AA, Chervenkov TG, Kashkov JK, Ivanov KD. Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients. Biostics Trends. 2015;9(6):393–401. doi:10.5582/bsts.2015.01170

26. Torre LA, Bray F, Siegel RL, Ferlay J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262

27. Hasakova K, Bezakova J, Vician M, Reis R, Zeman M, Herichova I. Gender-dependent expression of leading and passenger strand of miR-21 and miR-16 in human colorectal cancer and adjacent colonic tissues. Physiol Res. 2017;66(Supplement 4):S575–S582.
42. Kaneko I, Tanaka S, Oka S, et al. Lymphatic vessel density at the site of deepest penetration as a predictor of lymph node metastasis in submucosal colorectal cancer. *Dis Colon Rectum*. 2007;50(1):13–21. doi:10.1007/s10350-006-0745-5

43. Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. *Cancer Lett*. 2009;285(2):116–126. doi:10.1016/j.canlet.2009.04.031

44. Samadaian N, Modaresi MH, Mobasheri M, Ebrahim Zadeh Vesal R, Akrami SM. miRNA-21 expression analysis in 35 colorectal cancer. *Tehran Univ Med J*. 2014;72(5):301–306.

45. Bastaminejad S, Taherikalani M, Ghanbari R, Akhari A, Shabab N, Saidijam M. Investigation of microRNA-21 expression levels in serum and stool as a potential non-invasive biomarker for diagnosis of colorectal cancer. *Iran Biomed J*. 2017;21(2):106–113. doi:10.18869/acadpub.ibj.21.2.106

46. Baxter NN, Virnig DJ, Rothenberger DA, Morris AM, Jessurun J, Virnig BA. Lymph node evaluation in colorectal cancer patients: a population-based study. *J Natl Cancer Inst*. 2005;97(3):219–225. doi:10.1093/jnci/dji020